A Phase 2 interventional study of collagenase clostridium histolyticum (CCH) in Edematous Skin, sponsored by Endo Pharmaceuticals. Completed at 5 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-07.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.
Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 11th largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 2, and was the 9th registered.
71 studies on the registry are indexed under Cellulite; 3 are open to participants now.
Browse Cellulite studies →None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 34 across 65 interventional studies indexed under Cellulite.
Median enrollment 150 across the 15 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 2 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
18 studies in Cellulite by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 18 finished, 14 (78%) have results posted.
Among the 18 studies in Cellulite by Keenova Therapeutics plc, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2018, is one of 8 in phase 2, and was the 9th registered.
Keenova Therapeutics plc’s Cellulite studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Microbial Collagenase in Cellulite, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 18 in Cellulite:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety and effectiveness of different injection techniques of Collagenase Clostridium Histolyticum (CCH) for the treatment of adult women with mild, moderate or severe Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No participant will be assigned to treatment until all eligibility criteria have been satisfied. To qualify for the study a participant must:
Have evidence of cellulite in 2 bilateral treatment areas (defined as right and left buttocks or right and left posterolateral thighs) as assessed by the Investigator at the Screening visit, and fulfills the following requirements:
has at least 2 dimples from each treatment area that:
Exclusion Criteria:
Participants who meet any of the following criteria will be excluded from the study:
Has any of the following systemic conditions:
Has any of the following local conditions in the areas to be treated:
Has used any of the following for the treatment of EFP on the area to be treated within the timelines identified below or intends to use any of the following at any time during the course of the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Treatment I, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 milliliters (mL) aliquots (for a total injection volume of 0.3 mL). During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area).
Drug: collagenase clostridium histolyticum (CCH)
In Treatment II, CCH will be injected subcutaneously while the participant is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot. During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area).
Drug: collagenase clostridium histolyticum (CCH)
In Treatment III, CCH will be injected subcutaneously while the participant is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot. During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area).
Drug: collagenase clostridium histolyticum (CCH)
In Treatment IV, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL). During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5 mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area).
Drug: collagenase clostridium histolyticum (CCH)
In Treatment V, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL). During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2 mL of CCH (4 aliquots of 0.3 mL each). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area).
Drug: collagenase clostridium histolyticum (CCH)
Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22
Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 22 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).
Time frame: Day 22
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 43
Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 43 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).
Time frame: Day 43
Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 71
Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 71 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).
Time frame: Day 71
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 22
Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)
Time frame: Baseline, Day 22
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 43
Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)
Time frame: Baseline, Day 43
Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 71
Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)
Time frame: Baseline, Day 71
Change From Baseline of Dimple Volume by Treatment Region
For each treated buttock and thigh, 4 dimple parameters including the maximum length (largest straight line distance across the dimple), maximum width (largest straight line distance perpendicular to the maximum length measurement), surface are, and volume (between the base of the dimple and an interpolated surface) of the target dimple were assessed. A negative change from Day 1 indicated an improvement. Volume of Dimple from Day 1 pre-marking was analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the measurement for the average of left and right of treatment areas (that is, average of left buttock posterior and right buttock posterior; average of left thigh lateral, left thigh oblique, left thigh posterior, right thigh lateral, right thigh oblique, and right thigh posterior).
Time frame: Baseline, Day 22, Day 43, and Day 71
| Milestone | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 6 | 6 | 7 | 6 | 6 | 6 | 7 | 7 | 6 |
| Completed | 6 | 5 | 6 | 7 | 6 | 4 | 6 | 5 | 7 | 5 |
| Not completed | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol non-compliance | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 22 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).
| score on a scale | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22 | 1.08 (0.51 to 1.65) | 1.10 (0.46 to 1.74) | 0.75 (0.18 to 1.32) | 0.50 (-0.04 to 1.04) | 0.67 (0.10 to 1.24) | 0.20 (-0.44 to 0.84) | 0.83 (0.26 to 1.40) | 0.67 (0.09 to 1.25) | 1.00 (0.47 to 1.53) | 1.10 (0.46 to 1.74) |
Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 43 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).
| score on a scale | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 43 | 0.75 (0.18 to 1.32) | 1.40 (0.76 to 2.04) | 1.10 (0.47 to 1.73) | 0.57 (0.03 to 1.11) | 1.00 (0.43 to 1.57) | -0.01 (-0.64 to 0.64) | 1.17 (0.60 to 1.74) | 0.42 (-0.16 to 1.00) | 1.21 (0.69 to 1.74) | 0.70 (0.06 to 1.34) |
Aesthetic appearance improvement for each treatment area (buttocks or thighs) was assessed by a blinded central assessment, using a 5-point Likert scale with scores ranging from -1 to 3. Aesthetic improvement was scored as worse (-1), stayed the same (0), improved (1), much improved (2) and very much improved (3). The assessor evaluated the image at Day 71 in comparison with baseline and recorded the Likert score. Aesthetic appearance Likert scale scores were analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the response for the average of left and right of treatment area (that is, average of left buttock and right buttock or average of left thigh and right thigh).
| score on a scale | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 71 | 1.08 (0.51 to 1.65) | 0.92 (0.34 to 1.50) | 1.08 (0.51 to 1.65) | 0.43 (-0.11 to 0.97) | 1.00 (0.43 to 1.57) | 0.12 (-0.59 to 0.84) | 0.50 (-0.07 to 1.07) | 0.30 (-0.34 to 0.94) | 1.29 (0.76 to 1.81) | 0.60 (-0.04 to 1.24) |
Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)
| score on a scale | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 22 | -0.83 (-1.28 to -0.39) | -0.30 (-0.84 to 0.24) | -0.17 (-0.61 to 0.28) | -0.43 (-0.89 to 0.03) | -0.17 (-0.61 to 0.28) | -0.20 (-0.74 to 0.34) | -0.83 (-1.28 to -0.39) | -0.67 (-1.16 to -0.17) | -0.14 (-0.56 to 0.27) | -0.20 (-0.74 to 0.34) |
Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)
| score on a scale | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 43 | -0.92 (-1.36 to -0.47) | -0.40 (-0.94 to 0.14) | -0.40 (-0.89 to 0.09) | -0.43 (-0.89 to 0.03) | -0.50 (-0.95 to -0.05) | -0.40 (-0.94 to 0.14) | -0.83 (-1.28 to -0.39) | -0.67 (-1.16 to -0.17) | -0.36 (-0.77 to 0.06) | -0.60 (-1.14 to -0.06) |
Dimple depth depression for each treatment area was assessed by the Investigator using the Hexsel Cellulite Severity Scale (B). Dimple Depth Depression of Hexsel Cellulite Severity Scale (B) was assessed and graded as: no depression (0), superficial depressions (1), medium depth depressions (2) and deep depressions (3). A negative change in Hexsel CSS (B) from baseline indicated an improvement in depression depth. Change from Baseline in dimple depth depression of Hexsel Cellulite Severity Scale (B) was analyzed using linear mixed model with treatment arm, study visits, interaction of treatment arm and study visit as fixed effect. This model was fitted using the response for the average of left and right of treatment areas (that is, average of left buttock and right buttock; average of left thigh and right thigh)
| score on a scale | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) by Treatment Region at Day 71 | -1.17 (-1.61 to -0.72) | -0.33 (-0.83 to 0.16) | -0.08 (-0.53 to 0.36) | -0.29 (-0.74 to 0.17) | -0.67 (-1.11 to -0.22) | -0.75 (-1.36 to -0.14) | -0.83 (-1.28 to -0.39) | -1.40 (-1.94 to -0.86) | -0.36 (-0.77 to 0.06) | -0.80 (-1.34 to -0.26) |
For each treated buttock and thigh, 4 dimple parameters including the maximum length (largest straight line distance across the dimple), maximum width (largest straight line distance perpendicular to the maximum length measurement), surface are, and volume (between the base of the dimple and an interpolated surface) of the target dimple were assessed. A negative change from Day 1 indicated an improvement. Volume of Dimple from Day 1 pre-marking was analyzed using linear mixed model with treatment arm, study visit, interaction of treatment arm and study visit as fixed effects. This model was fitted using the measurement for the average of left and right of treatment areas (that is, average of left buttock posterior and right buttock posterior; average of left thigh lateral, left thigh oblique, left thigh posterior, right thigh lateral, right thigh oblique, and right thigh posterior).
| mm^3 | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 22 | -0.01 (-0.04 to 0.01) | -0.02 (-0.07 to 0.02) | -0.001 (-0.03 to 0.02) | -0.04 (-0.08 to -0.0001) | -0.01 (-0.04 to 0.01) | 0.00 (-0.05 to 0.05) | -0.01 (-0.04 to 0.01) | -0.01 (-0.06 to 0.03) | -0.04 (-0.06 to -0.01) | -0.04 (-0.09 to 0.01) |
| Day 43 | -0.02 (-0.05 to 0.00) | -0.03 (-0.08 to 0.02) | -0.02 (-0.05 to 0.00) | -0.04 (-0.08 to 0.00) | -0.01 (-0.04 to 0.01) | 0.01 (-0.04 to 0.06) | -0.01 (-0.04 to 0.01) | -0.02 (-0.07 to 0.02) | -0.04 (-0.07 to -0.02) | -0.06 (-0.11 to -0.01) |
| Day 71 | -0.02 (-0.05 to 0.00) | -0.02 (-0.07 to 0.02) | -0.04 (-0.06 to -0.01) | -0.02 (-0.07 to 0.02) | -0.01 (-0.04 to 0.02) | 0.04 (-0.02 to 0.09) | -0.02 (-0.05 to 0.01) | -0.02 (-0.07 to 0.03) | -0.05 (-0.07 to -0.02) | -0.05 (-0.09 to 0.00) |
Collected over Day 1 (after dosing) through Day 71. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/7 | 1/7 | 0/6 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/7 | 1/7 | 0/6 |
| HospitalizationSurgical and medical procedures | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 1/7 | 0/7 | 0/6 |
| Event | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 6/6 | 6/6 | 3/6 | 6/7 | 6/6 | 6/6 | 6/6 | 7/7 | 6/7 | 3/6 |
| Injection site bruisingGeneral disorders | 5/6 | 4/6 | 4/6 | 7/7 | 6/6 | 6/6 | 3/6 | 3/7 | 5/7 | 6/6 |
| Injection site noduleGeneral disorders | 3/6 | 2/6 | 4/6 | 6/7 | 5/6 | 5/6 | 0/6 | 3/7 | 3/7 | 5/6 |
| Injection site warmthGeneral disorders | 2/6 | 4/6 | 2/6 | 3/7 | 2/6 | 0/6 | 1/6 | 1/7 | 2/7 | 2/6 |
| Injection site haemorrhageGeneral disorders | 1/6 | 2/6 | 0/6 | 0/7 | 1/6 | 0/6 | 3/6 | 4/7 | 2/7 | 0/6 |
| Injection site discolourationGeneral disorders | 1/6 | 1/6 | 2/6 | 4/7 | 1/6 | 0/6 | 0/6 | 0/7 | 0/7 | 1/6 |
| Injection site pruritusGeneral disorders | 3/6 | 3/6 | 1/6 | 3/7 | 2/6 | 0/6 | 2/6 | 1/7 | 2/7 | 0/6 |
| Injection site swellingGeneral disorders | 1/6 | 0/6 | 0/6 | 1/7 | 1/6 | 0/6 | 1/6 | 2/7 | 1/7 | 1/6 |
| Injection site indurationGeneral disorders | 1/6 | 1/6 | 0/6 | 1/7 | 0/6 | 0/6 | 1/6 | 2/7 | 0/7 | 1/6 |
| Influenza-like illnessGeneral disorders | 0/6 | 0/6 | 0/6 | 0/7 | 1/6 | 0/6 | 0/6 | 0/7 | 0/7 | 0/6 |
Safety Population includes all participants who had at least 1 injection of study drug.
| Age, Continuous(years) | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 50.2 ± 9.85 | 44.7 ± 8.19 | 43.3 ± 10.95 | 45.6 ± 9.55 | 48.7 ± 15.95 | 52.2 ± 13.04 | 51.5 ± 11.93 | 49.0 ± 12.75 | 48.4 ± 10.00 | 39.8 ± 10.26 | 47.3 ± 11.17 |
| Sex: Female, Male(Participants) | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 6 | 6 | 7 | 6 | 6 | 6 | 7 | 7 | 6 | 63 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 3 | 6 | 3 | 1 | 1 | 2 | 5 | 3 | 32 |
| Not Hispanic or Latino | 2 | 2 | 3 | 1 | 3 | 5 | 5 | 5 | 2 | 3 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 2 | 1 | 0 | 1 | 0 | 3 | 1 | 3 | 14 |
| White | 3 | 6 | 4 | 6 | 6 | 5 | 5 | 4 | 6 | 3 | 48 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Weight(kg) | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 90.258 ± 30.2437 | 75.660 ± 15.2730 | 87.843 ± 23.6933 | 84.407 ± 20.2152 | 76.687 ± 13.3870 | 74.117 ± 13.9682 | 65.038 ± 17.0083 | 72.396 ± 15.6629 | 78.497 ± 12.0413 | 96.008 ± 14.9791 | 80.012 ± 19.0943 |
| Height(cm) | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 158.7 ± 3.67 | 162.2 ± 3.03 | 161.8 ± 2.14 | 164.4 ± 10.01 | 163.0 ± 6.90 | 162.3 ± 3.88 | 161.5 ± 8.96 | 167.4 ± 10.55 | 164.4 ± 8.96 | 165.2 ± 6.65 | 163.2 ± 7.18 |
| Body Mass Index (BMI)(kg/m^2) | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 35.92 ± 12.643 | 30.30 ± 6.387 | 33.65 ± 9.415 | 31.11 ± 6.277 | 29.13 ± 6.239 | 28.05 ± 4.669 | 24.78 ± 5.202 | 26.40 ± 7.330 | 29.01 ± 4.123 | 35.10 ± 3.929 | 30.27 ± 7.379 |
| Skin Category (Fitzpatrick Scale)(Participants) | Treatment I: CCH Shallow Injection, 3 Aliquots (Buttocks) | Treatment I: CCH Shallow Injection, 3 Aliquots (Thighs) | Treatment II: CCH Shallow Injection, 1 Aliquot (Buttocks) | Treatment II: CCH Shallow Injection, 1 Aliquot (Thighs) | Treatment III: CCH Deep Injection, 1 Aliquot (Buttocks) | Treatment III: CCH Deep Injection, 1 Aliquot (Thighs) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Buttocks) | Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots (Thighs) | Treatment V: CCH Shallow Injections, 4 Aliquots (Buttocks) | Treatment V: CCH Shallow Injections, 4 Aliquots (Thighs) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I (Pale White) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| II (Fair) | 1 | 2 | 1 | 0 | 2 | 1 | 1 | 2 | 2 | 0 | 12 |
| III (Darker White) | 0 | 2 | 0 | 0 | 2 | 3 | 3 | 0 | 1 | 0 | 11 |
| IV (Light Brown) | 2 | 2 | 3 | 6 | 2 | 1 | 1 | 0 | 3 | 3 | 23 |
| V (Brown) | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 3 | 7 |
| VI (Dark Brown or Black) | 3 | 0 | 1 | 0 | 0 | 1 | 0 | 3 | 1 | 0 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Ran from Sep 2018 to primary completion in Jan 2019, 4 months.
Results were first posted in Sep 2023, 4 years 7 months after primary completion. A results delay was requested in Jan 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase